20 articles
New NIH research challenges the popular idea that taurine levels reliably track biological aging, raising questions for supplement advocates.
The provided source does not match the article title; only a one-line digest reference to a June 2025 NIH taurine release is available, insufficient for a reliable summary.
Massive study of 270,000 people reveals higher tyrosine levels linked to reduced male lifespan, raising supplement safety questions.
University of Cologne researchers reveal how the amino acid leucine boosts cellular energy by preventing breakdown of critical mitochondrial proteins.
A 270,000-person study finds higher blood tyrosine levels associated with shorter lifespans in men, raising concerns about common focus supplements.
Massive study of 270,000 people finds higher tyrosine levels linked to shorter life expectancy in men but not women.
Common eye-health nutrient zeaxanthin strengthens immune T cells and enhances cancer treatment effectiveness in new research.
New analyses of vutrisiran show consistent benefits in diverse heart amyloidosis patients, with a long-term observational study now underway.
A quercetin, NR, urolithin A, and alpha-lipoic acid combination boosted remaining lifespan in aged mice by 33%, even on a Western diet.
Arginine supplements reduced toxic amyloid buildup, brain inflammation, and behavioral decline in fly and mouse Alzheimer's models.
New evidence suggests 500mg daily vitamin C cuts anxiety within two weeks, but whole fruits may offer safer, broader benefits.
OrsoBio's mitochondrial drug TLC-6740 added 4.5% more weight loss on top of tirzepatide in a Phase 2a trial, with bonus metabolic and cognitive benefits.
Voyager's VY1706 slashed tau protein up to 64% in primate brains after one IV dose, with no adverse effects found.
A quality improvement study found dialysis patients receiving liquid protein supplements had fewer, shorter hospital stays and better nutritional biomarkers.
Diranersen reduced tau biomarkers and slowed cognitive decline in early Alzheimer's patients, marking a milestone for tau-directed therapy.
Scientists discover tanycytes help clear toxic tau from the brain. When damaged, these cells may allow Alzheimer's progression.
An oral iron-targeting drug significantly slowed Multiple System Atrophy progression in a Phase 2 trial, with Phase 3 planning underway.
PulseSight's iron-regulating gene therapy slowed geographic atrophy growth in a first-in-human trial, with Phase 2 planned for 2026.
A 16-week study finds creatine amplifies the anti-inflammatory and neuroplasticity benefits of fast-movement resistance training in adults over 65.
Tectonic Therapeutic enrolls 191 patients in a global trial of TX45, a novel fusion protein targeting a deadly heart-lung condition.
